2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Stryker Corporation company profile · MedSurg and neurotechnology, orthopaedics, Mako robotics · history · financial snapshot · S&P 500 rank #99 · 史賽克公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | SYK (NYSE) |
| Company | Stryker Corporation (stryker.com) |
| GICS sector / industry | Health Care (XLV) / Health Care Equipment & Supplies |
| S&P 500 rank (by weight) | #99 · 0.17% (Oct 29, 2026) |
| Sector rank (by market cap) | #16 in Health Care (Oct 29, 2026) |
| Headquarters | Portage, Michigan, USA |
| Founded | 1941 in Kalamazoo, Michigan (incorporated in Michigan in 1946) |
| CEO | Kevin A. Lobo, chair and chief executive officer |
| Employees | About 56,000 worldwide (Dec 31, 2025) |
| Market cap | $119.58B (Oct 29, 2026, frozen benchmark) |
| SEC filings | SEC EDGAR — CIK 0000310764 |
WHAT IT DOES
Stryker Corporation is a medical technology company that makes surgical equipment, neurotechnology products and orthopaedic implants, and provides related services. Its products are sold in about 61 countries, and the United States accounted for $19.01B, or 76%, of fiscal 2025 net sales.
The business has two segments. MedSurg and Neurotechnology ($15.65B in fiscal 2025) covers surgical equipment, endoscopy, patient handling, emergency medical equipment and neurotechnology, including the Mako robotic-arm system. Orthopaedics ($9.47B) covers implants for hip, knee, shoulder, spine and trauma surgery.
Stryker sells capital equipment, implants and disposables together: the Mako installed base and the surgical equipment fleet pull through high-margin implant and service revenue. Growth comes from new products, robotic adoption, acquisitions — Inari Medical closed in February 2025 for $4.9B — and expansion in emerging markets.
BUSINESS SEGMENTS — FY2025 REVENUE
| Segment | Revenue | Share | YoY |
|---|---|---|---|
| MedSurg and Neurotechnology | $15.65B | 62.3% | +15.7% |
| Orthopaedics | $9.47B | 37.7% | +4.3% |
| Total | $25.12B | 100% | +11.2% |
HISTORY
| Year | Milestone |
|---|---|
| 1941 | Dr. Homer H. Stryker founds the business in Kalamazoo, Michigan. |
| 1946 | The company is incorporated in Michigan. |
| 1979 | Stryker completes its initial public offering. |
| 1998 | Stryker acquires Howmedica, expanding into orthopaedic implants. |
| 2012 | Kevin Lobo becomes chief executive officer. |
| 2013 | Stryker acquires Mako Surgical, entering robotic-arm assisted surgery. |
| 2016 | Stryker acquires Sage Products, adding patient-handling products. |
| 2022 | Stryker acquires Vocera, adding clinical communication technology. |
| 2025 | Stryker acquires Inari Medical for $4.9B, closing in February 2025. |
| 2025 | Stryker divests its US spinal implants business to VB Spine. |
| 2026 | Stryker creates the Ortho Tech business and recasts its segment presentation (June 26, 2026 8-K). |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT — FY2025
| Net sales | $25.12B (+11.2% YoY) |
| Gross profit | $16.07B (64.0% of sales) |
| Operating income | $4.90B (19.5% of sales) |
| Net earnings | $3.25B (+8.5% YoY) |
| Diluted EPS | $8.40 (vs $7.76 in FY2024) |
| Total assets | Not available |
| Total shareholders' equity | Not available |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
At #99 by weight and #16 in Health Care, Stryker is a core holding in the health care sleeve and a proxy for hospital capital spending and orthopaedic procedure volumes.
Its mix of capital equipment, implants and disposables gives the index exposure to both hospital investment cycles and ageing-driven procedure demand, two of the sector's main growth drivers.
SOURCES & METHODOLOGY
| Market data | Slickcharts S&P 500 by Weight snapshot, as of Oct 29, 2026 close (frozen benchmark per Jazz verdict doc 1514); price $311.75, rank #99, weight 0.17%, market cap $119.58B. |
| Financials | Stryker FY2025 Form 10-K (fiscal year ended Dec 31, 2025; filed February 11, 2026) and Q4/FY2025 results release (January 29, 2026). |
| Sector classification | GICS Health Care / Health Care Equipment & Supplies; XLV. |
| Library data | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 代碼 | SYK(紐約證券交易所) |
| 公司 | Stryker Corporation(stryker.com) |
| GICS 板塊/行業 | 醫療保健(XLV)/醫療保健設備與用品 |
| 標普500排名(按權重) | #99 · 0.17%(2026 年 10 月 29 日) |
| 板塊內排名(按市值) | 醫療保健第 16 名(2026 年 10 月 29 日) |
| 總部 | 美國密歇根州波蒂奇 |
| 成立 | 1941 年,美國密歇根州卡拉馬祖(1946 年於密歇根州註冊成立) |
| 行政總裁 | Kevin A. Lobo,董事長兼行政總裁 |
| 員工 | 全球約 56,000 人(2025 年 12 月 31 日) |
| 市值 | $119.58B(2026 年 10 月 29 日,凍結基準) |
| SEC 申報 | SEC EDGAR — CIK 0000310764 |
業務概覽
史賽克公司是一間醫療科技公司,生產手術設備、神經技術產品與骨科植入物,並提供相關服務。產品銷往約 61 個國家;美國佔 2025 財年淨銷售額 $19.01B,即 76%。
業務分為兩個板塊。醫療外科與神經技術(2025 財年 $15.65B)涵蓋手術設備、內窺鏡、病人搬運、急救醫療設備及神經技術,包括 Mako 機械臂系統。骨科($9.47B)涵蓋髖、膝、肩、脊柱及創傷手術植入物。
史賽克將資本設備、植入物與耗材一併銷售:Mako 裝機量與手術設備機隊帶動高利潤的植入物與服務收入。增長來自新產品、機械人普及、收購——Inari Medical 於 2025 年 2 月以 $4.9B 完成收購——以及新興市場擴張。
業務板塊 — FY2025 收入
| Segment | Revenue | Share | YoY |
|---|---|---|---|
| 醫療外科與神經技術 | $15.65B | 62.3% | +15.7% |
| 骨科 | $9.47B | 37.7% | +4.3% |
| 合計 | $25.12B | 100% | +11.2% |
歷史沿革
| Year | Milestone |
|---|---|
| 1941 | Homer H. Stryker 醫生於密歇根州卡拉馬祖創辦業務。 |
| 1946 | 公司於密歇根州註冊成立。 |
| 1979 | 史賽克完成首次公開發售。 |
| 1998 | 史賽克收購 Howmedica,擴展至骨科植入物。 |
| 2012 | Kevin Lobo 出任行政總裁。 |
| 2013 | 史賽克收購 Mako Surgical,進軍機械臂輔助手術。 |
| 2016 | 史賽克收購 Sage Products,新增病人搬運產品。 |
| 2022 | 史賽克收購 Vocera,新增臨床通訊技術。 |
| 2025 | 史賽克以 $4.9B 收購 Inari Medical,於 2025 年 2 月完成。 |
| 2025 | 史賽克將美國脊柱植入物業務出售予 VB Spine。 |
| 2026 | 史賽克成立 Ortho Tech 業務並重述板塊呈列(2026 年 6 月 26 日 8-K 表格)。 |
競爭地位
財務快照 — FY2025
| 淨銷售額 | $25.12B(+11.2% YoY) |
| 毛利 | $16.07B(佔銷售額 64.0%) |
| 經營收入 | $4.90B(佔銷售額 19.5%) |
| 淨利潤 | $3.25B(+8.5% YoY) |
| 稀釋每股盈利 | $8.40(2024 財年為 $7.76) |
| 總資產 | 暫無資料 |
| 股東權益總額 | 暫無資料 |
主要風險
對標普500的重要性
按權重計排名 #99、醫療保健板塊第 16 名,史賽克是醫療保健板塊的核心持股,也是醫院資本開支與骨科手術量的代表。
其資本設備、植入物與耗材組合,使指數同時受惠於醫院投資週期與老齡化帶動的手術需求——這是該板塊的兩大增長動力。
來源與方法
| 市場數據 | Slickcharts 標普500按權重快照,截至 2026 年 10 月 29 日收市(按 Jazz 裁決文件 1514 的凍結基準);股價 $311.75,排名 #99,權重 0.17%,市值 $119.58B。 |
| 財務數據 | 史賽克 2025 財年 10-K 表格(財年截至 2025 年 12 月 31 日;2026 年 2 月 11 日提交)及 2025 財年第四季業績公告(2026 年 1 月 29 日)。 |
| 板塊分類 | GICS 醫療保健/醫療保健設備與用品;XLV。 |
| 資料庫數據 | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-10-30 05:10 · updated 2026-11-15 00:05 · rev 6